Pathology and new insights in thyroid neoplasms in the 2022 WHO classification

被引:9
|
作者
Lebrun, Laetitia [1 ]
Salmon, Isabelle [1 ,2 ,3 ]
机构
[1] Univ Libre Bruxelles ULB, Erasme Univ Hosp, Hop Univ Bruxelles HUB, CUB Hop Erasme,Dept Pathol, Brussels, Belgium
[2] ULB, Ctr Microscopy & Mol Imaging CMMI, DIAPath, Gosselies, Belgium
[3] Univ Libre Bruxelles ULB, Erasme Univ Hosp HUB, Dept Pathol, Rue Meylemeersch 90, B-1070 Brussels, Belgium
关键词
Bethesda system; fine needle aspiration; molecular testing; screening; thyroid cancer; WHO classification; TERT PROMOTER MUTATIONS; ENCAPSULATED FOLLICULAR VARIANT; INTEROBSERVER VARIABILITY; ASSOCIATION GUIDELINES; GENETIC ALTERATIONS; VASCULAR INVASION; TASK-FORCE; CARCINOMA; CANCER; NODULES;
D O I
10.1097/CCO.0000000000001012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of reviewThe assessment of thyroid nodules is a common clinical problem, linked to the high incidence of thyroid nodules in the population and the low incidence of aggressive thyroid carcinoma. The screening is therefore one of the strengths of our patient care. Recently, the 2023 Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) and 2022 WHO classification of thyroid neoplasms have been released based on the definition of new entities and the growing impact of molecular testing. The aim of this review is to analyze how these upgrades can help us in the daily routine practice diagnosis of thyroid cancer.Recent findingsOur review is focused on the most frequent thyroid tumors derived from thyroid follicular cell. Fine needle aspiration (FNA) is the gold standard for the screening of thyroid nodules with very high levels of sensitivity and specificity. These sensitivity and specificity are improved by molecular testing, which refines the risk of malignancy. The 2023 TBSRTC integrates molecular data and the upgrades integrated in the 2022 WHO classification such as the 'low-risk neoplasms' and the 'high-grade follicular-cells derived carcinoma'. The morphological examination remains crucial since the capsular and/or vascular invasion are key features of malignancy in the follicular thyroid neoplasms. Low-risk neoplasms represent a clinical challenge since no specific guidelines are available. Challenges remain regarding oncocytic thyroid lesions, which are not associated with specific diagnostic molecular biomarkers. Molecular testing can help not only in deciphering the prognosis but also in the targeted therapeutic strategy.SummaryWhile molecular testing has succeeded to substantially improve the pre and postoperative diagnosis and risk stratification of thyroid tumors, the morphological examination is still central in the daily routine diagnosis of thyroid pathology. Future is the integrated diagnosis of clinical, morphological, molecular and epigenetic features with the help of artificial intelligence algorithms.
引用
收藏
页码:13 / 21
页数:9
相关论文
共 50 条
  • [41] Mucinous neoplasms of the vermiform appendix, Pseudomyxoma peritonei, and the new WHO classification
    Reu, S.
    Neumann, J.
    Kirchner, T.
    PATHOLOGE, 2012, 33 (01): : 24 - 30
  • [42] Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms
    Crippa, S.
    Partelli, S.
    Boninsegna, L.
    Falconi, M.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1928 - 1928
  • [43] Characterization of Clinical, Molecular, and Prognostic Features of the WHO 2022 Classification System for Myelodysplastic Neoplasms (MDS)
    Khanna, Vishesh
    Lu, Rong
    Kumar, Jyoti
    Stehr, Henning
    Spinner, Michael A.
    Silva, Oscar
    Fernandez-Pol, Sebastian
    Oak, Jean S.
    Tan, Brent
    Greenberg, Peter L.
    BLOOD, 2022, 140 : 6955 - 6957
  • [44] WHO classification of myeloid neoplasms and leukemia
    Wandt, Hannes
    Haferlach, Torsten
    Thiede, Christian
    Ehninger, Gerhard
    BLOOD, 2010, 115 (03) : 748 - 749
  • [45] Sinonasal neoplasms: Update from the WHO 2022
    Agaimy, Abbas
    PATHOLOGIE, 2023, 44 (04): : 233 - 239
  • [46] The Evolving Role of Pathology in New Developments, Classification, Terminology, and Diagnosis of Pancreatobiliary Neoplasms
    Reid, Michelle D.
    Lewis, Melinda M.
    Willingham, Field F.
    Adsay, N. Volkan
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2017, 141 (03) : 366 - 380
  • [47] What's new in the WHO 2022 classification of kidney tumours?
    Alaghehbandan, Reza
    Siadat, Farshid
    Trpkov, Kiril
    PATHOLOGICA, 2023, 115 (01) : 8 - 22
  • [48] Diagnostic principles of thyroid tumors in pathology Relevant changes due to the current WHO classification
    Theurer, Sarah
    Rawitzer, Josefine
    Ting, Saskia
    Schmid, Kurt Werner
    PATHOLOGE, 2021, 42 (01): : 125 - 139
  • [49] Molecular Pathology of Thyroid Tumors: Essential Points to Comprehend Regarding the Latest WHO Classification
    Chiba, Tomohiro
    BIOMEDICINES, 2024, 12 (04)
  • [50] Neuroendocrine Neoplasms of the Gastroenteropancreatic System: Pathology and Classification
    Anlauf, M.
    HORMONE AND METABOLIC RESEARCH, 2011, 43 (12) : 825 - 831